MD Anderson Cancer Center at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
MD Anderson Cancer Center takes part in 30 sessions at ESMO 2026 in Madrid, and exhibits at Booth 8006. Its program centres on targeted drugs, with a focus on KRAS G12C-mutant lung cancer, BRAF-mutant colorectal cancer and antibody-drug conjugates in prostate and ovarian cancer. Other sessions cover circulating tumour DNA to track treatment response, validating artificial intelligence for clinical use, and a vaccine for Lynch syndrome carriers.
| Organization | ESMO 2026 Attendance |
|---|---|
MD Anderson Cancer Center Houston, TX | |
Comprehensive cancer treatment and research centre of the University of Texas in Houston, Texas. | Booth Exhibiting at Booth 8006 Talk Fri Oct 23 13:30 Talk Fri Oct 23 14:30–14:45 Chair Fri Oct 23 16:15–17:45 Emerging therapeutic strategies in advanced prostate cancer Genitourinary cancers Abstract Fri Oct 23 16:47–16:52 Talk Fri Oct 23 17:15–17:35 New targets (ADCs, new biologies) Genitourinary cancers Satellite Fri Oct 23 18:45–19:10 Elacestrant in ESR1-mutant mBC: Establishing the Standard of Care Breast cancerBiomarkers & precision oncology Chair Sat Oct 24 08:30–10:00 Rapid oral 1: NSCLC, metastatic Lung & thoracic cancers Abstract Sat Oct 24 08:35–08:40 Abstract Sat Oct 24 08:45–09:00 Invited Discussant LBA73, 2719RO and 2700RO Lung & thoracic cancers Talk Sat Oct 24 09:10–09:30 Satellite Sat Oct 24 13:05–13:25 KRAS G12C Biology: A Unique Oncogenic Driver With Dual Impact Lung & thoracic cancers Satellite Sat Oct 24 14:00–14:15 A new chapter? The evolving role of ADCs in mCRC Gastrointestinal cancers Chair Sat Oct 24 14:45–16:15 Abstract Sat Oct 24 15:05–15:15 Abstract Sat Oct 24 15:15–15:27 Chair Sat Oct 24 16:30–18:00 Updates on myeloid neoplasms with a focus on medical oncology practice Haematological malignancies Talk Sat Oct 24 17:10–17:30 Current treatment landscape of AML based on a comprehensive genomic assessment Haematological malignancies Abstract Sun Oct 25 08:30–08:35 Abstract Sun Oct 25 08:30–08:35 4244RO - NeoCOAST-2: Association of ctDNA clearance with clinical outcomes in a global platform Phase 2 perioperative trial Biomarkers & precision oncology Abstract Sun Oct 25 09:19–09:24 Talk Sun Oct 25 10:45–11:00 Satellite Sun Oct 25 13:10–13:25 Emerging evidence in BRAFV600E-mutant mCRC Gastrointestinal cancersBiomarkers & precision oncology Satellite Sun Oct 25 13:55–14:25 From the clinic: Applying precision medicine in practice Gastrointestinal cancersBiomarkers & precision oncology Abstract Sun Oct 25 15:15–15:25 Talk Sun Oct 25 15:30–15:50 Pathological response for the win Melanoma & skin cancers Abstract Sun Oct 25 16:30–16:42 LBA5 - Krascendo 1: efficacy and safety of divarasib (diva) vs sotorasib (soto) or adagrasib (ada) in previously treated locally advanced or metastatic KRAS G12C-mutated NSCLC Lung & thoracic cancersGastrointestinal cancers Chair Sun Oct 25 16:30–18:00 Rapid oral: Supportive and palliative care Nursing & supportive care Abstract Sun Oct 25 16:45–16:55 Invited Discussant 3469RO, 3085RO and 3895RO Nursing & supportive care Chair Mon Oct 26 08:30–10:00 Chair Mon Oct 26 08:30–10:00 Talk Mon Oct 26 09:15–09:30 Abstract Mon Oct 26 09:22–09:37 Talk Mon Oct 26 10:35–10:55 Biology and mechanisms of action of novel immunotherapies Lung & thoracic cancers Satellite Mon Oct 26 13:05–13:25 Charting the Path Forward in KRAS G12C Lung Cancer Lung & thoracic cancers Talk Mon Oct 26 14:45–15:00 Chair Mon Oct 26 14:45–16:15 Chair Mon Oct 26 14:45–16:15 Abstract Mon Oct 26 15:44–15:49 Abstract Mon Oct 26 15:49–15:59 Talk Mon Oct 26 16:30–16:45 IO-based systemic therapy (incl pt selection) Sarcoma, CNS, head & neck and rare cancers Satellite Mon Oct 26 19:25–19:50 Managing Complexity: Sequencing HER2-Directed Therapies After Progression Lung & thoracic cancersBiomarkers & precision oncology |
Instantly find 20 buyers from MD Anderson Cancer Center
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction